How many drugs treat E. Coli Pyelonephritis?

Drug Landscape tracks 10 marketed treatments for E. Coli Pyelonephritis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/e-coli-pyelonephritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

E. Coli Pyelonephritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

E. Coli Pyelonephritis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating E. Coli Pyelonephritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Cystadane	BETAINE	Recordati	Methylating Agent [EPC]		1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Cystadane	Cystadane	Mayo Clinic
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Baxter · 2 drugs in E. Coli Pyelonephritis
· 2 drugs in E. Coli Pyelonephritis
Assistance Publique - Hôpitaux de Paris · 1 drug in E. Coli Pyelonephritis
Bayer AG · 1 drug in E. Coli Pyelonephritis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in E. Coli Pyelonephritis
Mayo Clinic · 1 drug in E. Coli Pyelonephritis
Merck & Co. · 1 drug in E. Coli Pyelonephritis
Poitiers University Hospital · 1 drug in E. Coli Pyelonephritis
Recordati · 1 drug in E. Coli Pyelonephritis
University Hospital Tuebingen · 1 drug in E. Coli Pyelonephritis
Allergan · 1 drug in E. Coli Pyelonephritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in E. Coli Pyelonephritis:

Cite this brief

Drug Landscape (2026). E. Coli Pyelonephritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/e-coli-pyelonephritis. Accessed 2026-06-10.

E. Coli Pyelonephritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing